GeNeuro Phase IIb Launch And Partner's Equity Investment
This article was originally published in Scrip
GeNeuro SA. has begun its proof-of-concept Phase IIb study, CHANGE-MS, with lead product GNbAC1, an antibody targeting the protein MSRV-Env expressed in multiple sclerosis (MS). Servier, the company's development partner, has also exercised its equity investment option to become a minority shareholder in GeNeuro by buying shares from existing shareholder Eclosion2.
Register for our free email digests: